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andeeps_iop@bkc.Abstract A rapid and simple high performance liquid chromatography (HPLC) method with a
UV detection (241 nm) was developed and validated for estimation of eplerenone from spiked
human plasma. The analyte and the internal standard (valdecoxib) were extracted with a mixture of
dichloromethane and diethyl ether. The chromatographic separation was performed on a HiQSil
C-18HS column (250 mm 4.6 mm, 5 mm) with a mobile phase consisting of acetonitrile:water
(50:50, v/v) at ﬂow rate of 1 mL/min. The calibration curve was linear in the range 100–3200 ng/mL
and the heteroscedasticity was minimized by using weighted least squares regression with weighting
factor 1/X.
& 2012 Xian Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Eplerenone is chemically Pregn-4-ene-7,21-dicarboxylic acid,
9,11-epoxy-17-hydroxy-3-oxo-, g-lactone, methyl ester,
(7a,11a,17a), an antihypertensive drug that is highly selective
aldosterone receptor antagonist (SARA) [1,2].rsity. Production and hosting
n Jiaotong University.
.006
2555860;
met.edu (S. Sonawane).A literature search revealed a few quantitative analytical
methods for estimation of eplerenone [3,4]; further, very few
methods described the quantiﬁcation of eplerenone in biolo-
gical ﬂuids [5,6]; these methods include LC-MS, which
requires expensive instrumentation not available in conven-
tional bioanalytical laboratory. Thus, it was decided to
develop a rapid, economical and simple method which was
based on liquid–liquid extraction (LLE) for sample prepara-
tion and HPLC with UV detection for quantiﬁcation of
eplerenone from spiked human plasma.2. Experimental
2.1. Equipment and materials
The HPLC system used consisted of a pump PU-2080 plus
(Jasco Corporation, Japan) with a Rheodyne loop injector of
capacity 100 mL. Detection was carried out by a UV-2075
Table 1 Area ratios from calibration experiments.
CC no. Amount of
drug (ng/mL)
Area ratio
(mean7SD, n¼6)
CC-1 100 0.1270.01
CC-2 200 0.2370.01
CC-3 400 0.4970.02
CC-4 800 0.8970.07
CC-5 1600 1.9570.11
CC-6 3200 3.7070.35
Table 2 Bank responses and LLOQ peak areas for
eplerenone.
Sr. no. Blank
response (mV)
Peak areas at
LLOQ (mV)
1 3978 43,254
2 4025 55,462
3 4825 60,415
4 3746 53,944
5 4482 57,169
6 3248 51,543
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tography software version 1.50.
Pharmaceutical grade eplerenone and valdecoxib used as an
internal standard were kindly supplied as a gift sample from
Hetero Drug Laboratories, Hyderabad, India. Blank human
plasma was procured as a gift sample from the Arpan Blood
Bank, Nashik, India. Plasmas from six sources were mixed
thoroughly to get pooled blank plasma. Acetonitrile and water
used in analysis were of HPLC grade. Other chemicals used in
the study were of AR grade. All chemicals were purchased from
SD Fine Chemicals, Mumbai, India. The 0.45 mm Nylon ﬁlter
papers were purchased from Pall India Pvt. Ltd., Mumbai, India.
2.2. Methods
2.2.1. Preparation of calibration curve (CC) standards and
quality control (QC) samples
The stock solution (100 mg/mL) of eplerenone was prepared in
methanol and this was then appropriately diluted with methanol
to get working standard solutions with concentrations of 2, 4, 8,
16, 32 and 64 mg/mL. Aliquots of 0.95 mL of blank human
plasma were spiked with 50 mL of the working standard solutions
to get CC standards containing 100, 200, 400, 800, 1600 and
3200 ng/mL of eplerenone. The QC samples were similarly
prepared to contain three concentrations [250 ng/mL low quality
control (LQC), 1000 ng/mL middle quality control (MQC) and
3000 ng/mL high quality control (HQC)].
2.2.2. Sample preparation
An aliquot of spiked human plasma sample (1 mL) was taken
in six different 15 mL stoppered test tubes followed by
addition of 50 mL of internal standard working solution
(10 mg/mL) and was vortex-mixed for 1 min. To this solution,
5 mL of dichloromethane:diethyl ether (4:6, v/v) was added
and the content of the tubes was mixed in an inclined position
on a reciprocating shaker at 100 stroke/min for 30 min and
centrifuged at 3000 rpm for 10 min to effect phase separation.
The supernant organic layer (4 mL) was transferred to another
tube and evaporated to dryness under stream of nitrogen.
Further, the residue was reconstituted in 250 mL of mobile
phase and subjected to chromatographic analysis.
2.2.3. Chromatographic conditions
Chromatographic analysis was performed on a HiQsil C-18HS
column (250 mm 4.6 mm, 5 mm), which was preceded by a
Hypersil BDS C18 guard column (20 mm 4 mm). The
mobile phase consisted of a mixture of acetonitrile:water
(50:50, v/v), the ﬂow rate was 1 mL/min and the detection
was carried out at 241 nm.
2.2.4. Calibration studies
All calibration standards were analyzed in six replicates and
the data of concentrations and corresponding area ratios of
eplerenone and internal standard were subjected to
unweighted and weighted least squares linear regression. The
equations generated from these regression analyses were used
to calculate the interpolated concentrations of the CC stan-
dards and the % relative error (% RE) was calculated for each
CC standard. The calibration model that resulted in minimum
total % RE for interpolated concentrations of the CC
standards was selected as the one that gave the least error.2.2.5. Validation
The developed method was validated as per the recommenda-
tions of US-FDA Guidance for Industry: Bioanalytical Meth-
ods Validation [7]. Selectivity was studied at the lower limit of
quantiﬁcation (LLOQ) of 100 ng/mL by comparing blank
responses of plasma from six different sources with peak areas
afforded by the LLOQ samples.
Accuracy was estimated as the mean RE while the precision
was measured in terms of RSD. The recovery of the extraction
procedure was calculated by comparing the peak areas of the
processed QC samples to those of corresponding standard
dilutions. Stability of eplerenone in human plasma was
evaluated under various conditions viz. three freeze–thaw
cycles, stability at 20 1C for 30 days and stability at room
temperature for 6 h. The amount of the drug in the stability
samples was found out and the % nominal and % relative
standard deviation of the determination were calculated.3. Results and discussion
Chromatographic conditions were selected after several trials
on different columns using mobile phases comprising of
acetonitrile and water in different proportions. The HiQSil
C-18 column and mobile phase of acetonitrile:water (50:50, v/
v) gave adequate resolution and satisfactory peak shapes for
eplerenone and internal standard. The detection wavelength of
241 nm was chosen because it was the lmax of eplerenone.
When liquid–liquid extraction was performed using different
solvents like diethyl ether, dichloromethane, ethylacetate,
chloroform and toluene, it was found that both the drug
and internal standard were comparably extracted with dichlor-
omethane. The extraction recovery for eplerenone was 80%
while that for valdecoxib was 82%. A mixture of dichlor-
omethane and diethyl ether is less polar and lighter than
Figure 1 HPLC chromatograms of (A) blank plasma extract and (B) eplerenone and internal standard (valdecoxib) extracted from
plasma.
Table 4 Results of stability studies for eplerenone.
QC level Stability at RT Stability at 20 1C Freeze–thaw stability
% Nominal RSD (%) % Nominal RSD (%) % Nominal RSD (%)
LQC 102.23 4.97 104.93 5.03 103.34 3.87
HQC 104.58 3.46 105.21 6.01 98.45 4.75
Table 3 Results of accuracy and precision studies for eplerenone.
Level Concentration
added (ng/mL)
Intra-day (n¼5) Inter-day (n¼5) Recovery
(n¼5)
Mean concentration
found (ng/mL)
RE
(%)
RSD
(%)
Mean concentration
found (ng/mL)
RE
(%)
RSD
(%)
LQC 250 255.87 2.35 6.28 255.58 2.23 5.45 80.75
MQC 1000 947.48 5.25 8.97 976.19 2.38 5.80 81.23
HQC 3000 3141.81 4.73 6.01 3070.23 2.34 5.79 74.35
IS – – – – – – – 82.20
P. Gide et al.392dichloromethane; it is less likely to coextract interferents and
is easily transferable. Thus, it was decided to try a mixture of
dichloromethane and diethyl ether as the extracting solvent.
During optimization experiments, dichloromethane:diethyl
ether (4:6, v/v) gave satisfactory recovery of eplerenone and
valdecoxib. During the calibration experiments it was revealed
that the standard deviation of area ratios of CC standards
increased with concentration indicating a need for weighted
regression. Thus, weighted linear regression with weighing
factor of 1/X was selected as the calibration model which
resulted in the equation Y¼0.0012Xþ0.0030. The area ratios
of calibration experiments are depicted in Table 1. During
validation studies it was found that the peak areas for the
LLOQ samples were more than ﬁve times the blank responses
obtained using six different plasma sources as can be seen
in Table 2. This proved that the method was selective at the
LLOQ of 100 ng/mL. The chromatogram of blank plasma
extract shown in Fig. 1(A) shows the lack of signiﬁcant
interference at the retention times of eplerenone and internal
standard. The representative chromatogram of MQC sample
is shown in Fig. 1(B). The US-FDA Guidance requires that
the RE should be within715%, while the RSD should be less
than 15%. The results of assay precision, accuracy and
extraction efﬁciency are shown in Table 3. The results ofstability evaluation of eplerenone are presented in Table 4.
Analysis of LQC and HQC samples subsequent to various
stability cycles viz. three freeze–thaw cycles, stability at
20 1C for 30 days and stability at room temperature for
6 h indicated that eplerenone was stable in human plasma
under these conditions.Acknowledgment
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